Evidence map›Paper›PMID 30713660›Full record

ArticleToxicology research2019

Reliability and relevance evaluations of REACH data.

Ellen Ingre-Khans, Marlene Ågerstrand, Anna Beronius, Christina Rudén

Abstract read
In one paragraph

Article in Toxicology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ellen Ingre-KhansDepartment of Environmental Science and Analytical Chemistry , Stockholm University , 106 91 Stockholm , Sweden . Email: ellen.ingre-khans@aces.su.se ; Tel: +46 (0)8 6747337.ORCID 0000-0002-4371-2847
Marlene ÅgerstrandDepartment of Environmental Science and Analytical Chemistry , Stockholm University , 106 91 Stockholm , Sweden . Email: ellen.ingre-khans@aces.su.se ; Tel: +46 (0)8 6747337.ORCID 0000-0003-2697-2310
Anna BeroniusInstitute of Environmental Medicine , Karolinska Institutet , 171 77 Stockholm , Sweden.ORCID 0000-0001-9494-5395
Christina RudénDepartment of Environmental Science and Analytical Chemistry , Stockholm University , 106 91 Stockholm , Sweden . Email: ellen.ingre-khans@aces.su.se ; Tel: +46 (0)8 6747337.ORCID 0000-0002-9193-1147

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulatory authorities rely on hazard and risk assessments performed under REACH for identifying chemicals of concern and to take action. Therefore, these assessments must be systematic and transparent. This study investigates how registrants evaluate and report data evaluations under REACH and the procedures established by the European Chemicals Agency (ECHA) to support these data evaluations. Data on the endpoint repeated dose toxicity were retrieved from the REACH registration database for 60 substances. An analysis of these data shows that the system for registrants to evaluate data and report these evaluations is neither systematic nor transparent. First, the current framework focuses on reliability, but overlooks the equally important aspect of relevance, as well as how reliability and relevance are combined for determining the adequacy of individual studies. Reliability and relevance aspects are also confused in the ECHA guidance for read-across. Second, justifications for reliability evaluations were mainly based on studies complying with GLP and test guidelines, following the Klimisch method. This may result in GLP and guideline studies being considered reliable by default and discounting non-GLP and non-test guideline data. Third, the reported rationales for reliability were frequently vague, confusing and lacking information necessary for transparency. Fourth, insufficient documentation of a study was sometimes used as a reason for judging data unreliable. Poor reporting merely affects the possibility to evaluate reliability and should be distinguished from methodological deficiencies. Consequently, ECHA is urged to improve the procedures and guidance for registrants to evaluate data under REACH to achieve systematic and transparent risk assessments.

Identifiers

PMID30713660
PMCPMC6334497

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.